Safety Profile

Welchol Delivers Efficacy Without Being Systemically Absorbed¹

Welchol does not enter the bloodstream, so you can provide add-on efficacy without systemic absorption.

• Welchol binds to bile acids in the intestine without being metabolized by the liver and kidneys

• No dosage adjustment is required in patients with hepatic or mild to moderate renal impairment. Welchol has not been studied in severe renal impairment

Contraindications

Welchol is contraindicated in patients with:

• A history of bowel obstruction
• Serum TG concentrations >500 mg/dL
• A history of hypertriglyceridemia-induced pancreatitis

In T2DM studies

• Incidence of hypoglycemia was similar between the Welchol and placebo groups (3.0% vs 2.3%)¹
  • No incidence of severe hypoglycemia was reported¹
• Welchol was not associated with weight gain¹

Most common adverse reactions¹

Welchol may increase triglyceride levels, especially in patients on a sulfonylurea- or insulin-based therapy. Periodic monitoring of lipid parameters including TG and non–HDL-C levels is recommended. The long-term effect of hypertriglyceridemia on the risk of coronary artery disease is uncertain.

Please see Important Safety Information about Welchol below